Finsbury Worldwide Pharmaceutical Trust PLC (the "Company")
Results of a General Meeting held on 2 March 2010
The Company is pleased to announce that at the General Meeting held today the
resolution to renew the Company's share buy-back authority was passed with a
substantial majority.
The level of proxy votes received is shown below.
Resolution Votes For % Votes % Total Votes Votes
Against Cast
Withheld*
Special Resolution
1. To authorise the 21,715,462 99.65 76,869 0.35 21,792,331 1,187
Company to make
market purchases
of up to a
maximum of
6,716,138 of its
own Ordinary
shares, being
14.99% of the
issued share
capital as at
today's date.
* Please note that `Vote withheld' is not a vote in law and is not counted in
the calculation of the proportion of votes `For' and `Against `a resolution.
A copy of the above document has been submitted to the UK Listing Authority,
and will shortly be available for inspection at the UK Listing Authority's
Document Viewing Facility, which is situated at:
Financial Services Authority
25 The North Colonnade
Canary Wharf
London E14 5HS
- ENDS-
For further information please contact:
Mark Pope Frostrow Capital LLP - Company Secretary 0203 008 4913
S:\FWPT\Project GM\Reuslts og GM held on 2 March 2010.htm
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.